

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.								
Substi	itute for form 1449	A/PTO			Complete if Known			
				Application Number	09/189,543			
INF	ORMATIO	N D	SCLOSURE	Filing Date	November 10, 1998	E]
STA	TEMENT I	BY A	APPLICANT	First Named Inventor	CHEE	유		
				Group Art Unit	1631	S	_γ _P	_
	(use as many she	eets as	necessary)	Examiner Name	Marschel, A.	Z	-20	T
Sheet	1	of	2	Attorney Docket Number	A-66828-1/RMS/DCF	T	0	T

	U.S. PATENT DOCUMENTS										
6	Examiner Installation	Cite No.1	U.S. Patent Document Number Kind Co (if know		Date of Publication of Cited Document MM-DD-YYYY	Pages, Column Ches, Where Relevant Passages or Research Figures Appear					
/ •	AM	ક]/	5,604,097	Brenner	02/1997						
. 6	8 500T	2.	5,763,175	Brenner	06/1998						
74 C	P (laŭ 🏻	5,780,231	Brenner	07/1998						
Ĕ,	V	*	5,795,714	Cantor et al.	08/1998						
VE	PADEM										
		<u> </u>									
		<u> </u>									
		┡—									
		<u> </u>			_						
		l		1							

						FOREIGN PATENT DOCUMEN	NTS	<u> </u>	
Examiner Initials*	Cite No.1	Foreign Office ³	Number ⁴	nent Kind Co (if know		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
AM	5	wo	96/30392		Al	Ciba-Geigy AG	10/1996		
_	6	wo	97/46704		Al	Lynx Therapeutics, Inc.	12/1997		
	7	WO	98/31836	-	Al	Hyseq, Inc.	07/1998		
4	8	wo	99/64867		Al	Amersham Pharmacia Biotech UK Ltd.	12/1999		
									+-
									#
			l						

Examiner Signature	Autin Marseld	Date Considered 6-14-02	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449B/PTO **Application Number** 09/189,543 INFORMATION DISCLOSURE November 10, 1998 Filing Date STATEMENT BY APPLICANT First Named Inventor CHEE 1631 **Group Art Unit** (use as many sheets as necessary) 0 **Examiner Name** Marschel, A. Sheet √of 2 Attorney Docket Number A-66828-1/RMS/DCF OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS THER PRIOR ART - NON FALENT Extra designation of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate), title of the article (when appropriate) are designated as a second control of the article (when appropriate) and the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriate) are designated as a second control of the article (when appropriated as a second control of the article (when appropriated as a second control of the article (when appropriated as a second control of the article (when appropriated as a second control of the article (when appropriated as a second control of the article (when appropriated as a second control of the article (when appropriated as a second control of the article Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Initials* "A Sequencing Method Based on Real-Time Pyrophosphate," Science, 281:363-365 M 6-14-02 Examiner Date Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 8086 1499B.FRM (I/01) 1078611

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.